Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for with an alkylating payload, developed for the treatment of adult patients with multiple myeloma. The company's PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells. It offers OPD5, OPDC3, and Gliopep for the treatment of hematological or solid tumors, and glioblastoma. The company also provides Small Polypeptide based Killer Engagers (SPiKE) platform that is designed to bind to both NK-cells and specific targets on various cancer cells. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
Frequently asked questions
What sector does Oncopeptides AB (ONCO) operate in?
Oncopeptides AB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Oncopeptides AB (ONCO) current stock price?
As of the latest data, Oncopeptides AB stock price is SEK 1.58, with a previous close of SEK 1.57. Oncopeptides AB gained SEK 0.01 in the last trading session, representing a 0.32% increase.
What is Oncopeptides AB (ONCO) current market capitalization?
Oncopeptides AB market cap is approximately 600.64 million.
What is Oncopeptides AB (ONCO) Earnings Per Share (EPS)?
The trailing EPS is -SEK 0.87, and the forward EPS is -SEK 0.25.
What is Oncopeptides AB (ONCO) EBITDA?
Oncopeptides AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -40.70 million.
Does Oncopeptides AB (ONCO) pay dividends?
No. Oncopeptides AB does not pay a dividend.
When is Oncopeptides AB (ONCO) next earnings report?
Oncopeptides AB is expected to release its next earnings report on June 30, 2026.
What is Oncopeptides AB (ONCO) beta (volatility) score?
Oncopeptides AB has a beta of -1.328, indicating lower volatility than the overall market.
